MindWalk Holdings (HYFT) Asset Writedowns and Impairment (2020 - 2025)
MindWalk Holdings (HYFT) reported Asset Writedowns and Impairment of $2719.6 for Q2 2025, down 99.9% year-over-year from $2.9 million in Q2 2024, and down 99.9% quarter-over-quarter from $2.9 million in Q2 2024.
MindWalk Holdings (HYFT) Asset Writedowns and Impairment (2020 - 2025) Analysis & Trends
MindWalk Holdings (HYFT) has 5 years of Asset Writedowns and Impairment data on file, last reported at $2719.6 in Q2 2025.
- Asset Writedowns and Impairment for Q2 2025 came in at $2719.6, down 99.9% year-over-year; the trailing twelve-month figure through Apr 2025 was $3.0 million (changed 0.09% YoY), and the FY2025 annual result was $15.2 billion, up 532718.52% from the prior year.
- Asset Writedowns and Impairment eased to $2719.6 in Q2 2025 per HYFT's latest filing, from $2.9 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $2.9 million in Q2 2024 and troughed at -$34307.3 in Q2 2021.
- A 4-year average of $327829.0 and a median of $2.33 in 2022 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2022 and 2025: Asset Writedowns and Impairment surged 483.95% in 2022, then tumbled 99.9% in 2025.
- A 4-year view of Asset Writedowns and Impairment shows it stood at -$16.7 in 2021, then surged by 113.96% to $2.33 in 2022, then surged by 122362339.1% to $2.9 million in 2024, then sank by 99.9% to $2719.6 in 2025.
- Business Quant data shows HYFT's Asset Writedowns and Impairment at $2719.6 in Q2 2025, $2.9 million in Q2 2024, and $2.33 in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 2,719.56 |
| Apr 30, 2025 | 2,719.56 |
| Apr 30, 2024 | 2.85 Mn |
| Apr 30, 2024 | 2.85 Mn |
| Jul 31, 2022 | 2.33 |
| Jul 31, 2022 | 2.33 |
| Apr 30, 2022 | 131,723.85 |
| Apr 30, 2022 | 131,723.85 |
| Jan 31, 2022 | 131.94 |
| Jan 31, 2022 | 131.94 |
| Oct 31, 2021 | -16.70 |
| Oct 31, 2021 | -16.70 |
| Jul 31, 2021 | -2,441.95 |
| Jul 31, 2021 | -2,441.95 |
| Apr 30, 2021 | -34,307.30 |
| Apr 30, 2021 | -34,307.30 |
| Jan 31, 2021 | -1,554.60 |
| Jan 31, 2021 | -1,554.60 |
| Oct 31, 2020 | -3,781.65 |
| Oct 31, 2020 | -3,781.65 |